C. Escobar

A. Bayés‐Genís, S. Manzano, A. Bardají, 2018, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

Comments on the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease.

A. Evangelista, L. Pérez de Isla, C. Escobar, 2018, Revista espanola de cardiologia.

Comments on the 2018 ESC/EACTS Guidelines for Myocardial Revascularization.

A. Evangelista, R. Vazquez, H. Bueno, 2019, Revista espanola de cardiologia.

[Efficacy of percutaneous coronary intervention in patients with chronic ischaemic heart disease].

C. Escobar, J. Divisón, 2016, Semergen.

Selection of the Best of 2017 in Clinical Cardiology. Therapeutic Novelties.

V. Barrios, C. Escobar, M. Ruiz-Ortíz, 2018, Revista espanola de cardiologia.

Selection of the Best of 2016 in Clinical Cardiology: Therapeutic Novelties.

V. Barrios, C. Escobar, J. Cosín-Sales, 2017, Revista espanola de cardiologia.

High resting heart rate: a cardiovascular risk factor or a marker of risk?

V. Barrios, C. Escobar, 2008, European heart journal.

The Role of Red Yeast Rice Based Preparations for Non-Pharmacological Correction of Dyslipidemia in Patients with Low and Moderate Cardiovascular Risk (Expert Opinion)

S. Shalnova, C. Escobar, O. Drapkina, 2020 .

Clinical benefits of pitavastatin: focus on patients with diabetes or at risk of developing diabetes.

V. Barrios, C. Escobar, 2016, Future cardiology.

Relative safety profiles of high dose statin regimens

V. Barrios, C. Escobar, R. Echarri, 2008, Vascular health and risk management.

Combined therapy in the treatment of hypertension

V. Barrios, C. Escobar, 2010, Fundamental & clinical pharmacology.

Beating the clock: reducing cardiovascular risk by rapid blood pressure reduction with olmesartan

V. Barrios, C. Escobar, 2010, Expert opinion on pharmacotherapy.

New Data on ONTARGET: More Confusion?

V. Barrios, C. Escobar, R. Echarri, 2010, Journal of clinical hypertension.

Gender differences in the diagnosis and treatment of left ventricular hypertrophy detected by different electrocardiographic criteria. Findings from the SARA study

V. Barrios, C. Escobar, A. Calderón, 2010, Heart and Vessels.

Chronic kidney disease: the forgotten cardiovascular risk factor

V. Barrios, C. Escobar, R. Echarri, 2009, International journal of clinical practice.

High doses of lercanidipine are better tolerated than other dihydropyridines in hypertensive patients with metabolic syndrome: results from the TOLERANCE study

J. Segura, V. Barrios, C. Escobar, 2008, International journal of clinical practice.

High heart rate: more data for a question unresolved.

V. Barrios, C. Escobar, 2009, The American journal of cardiology.

High heart rate: more than a risk factor. Lessons from a clinical practice survey.

V. Barrios, C. Escobar, C. de Pablo, 2009, International journal of cardiology.

Diagnosis of heart failure in elderly patients: a clinical challenge

C. Escobar, L. Manzano, J. L. Santiago-Ruiz, 2011, European journal of heart failure.

Emerging drug combinations to optimize renovascular protection and blood pressure goals

V. Barrios, C. Escobar, R. Echarri, 2012, International journal of nephrology and renovascular disease.

The Modification of Diet in Renal Disease study examined the effects of dietary protein restriction

V. Barrios, C. Escobar, R. Echarri, 2012 .

Blood pressure control in hypertensive women aged 65 years or older in a primary care setting. MERICAP study.

V. Barrios, C. Escobar, V. Bertoméu, 2011, Revista espanola de cardiologia.

Regression of left ventricular hypertrophy in diabetics by a candesartan-based regimen in clinical practice.

V. Barrios, C. Escobar, A. Calderón, 2007, Diabetes research and clinical practice.

Diabetes mellitus en la población hipertensa asistida en Atención Primaria en España.Grado de control tensional y lipídico

C. Escobar, A. Calderón, V. Barrios, 2007 .

Candesartan in the treatment of hypertension: what have we learnt in the last decade?

V. Barrios, C. Escobar, 2011, Expert opinion on drug safety.

Does CHA₂DS₂-VASc score select patients who will benefit most from anticoagulation? Response.

V. Barrios, C. Escobar, 2014, Revista espanola de cardiologia.

Blood pressure goal achievement with olmesartan medoxomil-based treatment: additional analysis of the OLMEBEST study

M. Böhm, V. Barrios, C. Escobar, 2009, Vascular health and risk management.

[Comments on the ESC/EAS guidelines for the management of dyslipidaemias 2011. A report of the Task Force of the Clinical Practice Guidelines Committee of the Spanish Society of Cardiology].

A. Fernández-Ortiz, V. Barrios, C. Escobar, 2011, Revista espanola de cardiologia.

Fixed combinations in the management of hypertension: perspectives on lercanidipine – enalapril

V. Barrios, C. Escobar, R. Echarri, 2008, Vascular health and risk management.

Importance of Early Identification of Renal Disease

V. Barrios, C. Escobar, R. Echarri, 2010 .

Influence of renal function on anticoagulation control in patients with non‐valvular atrial fibrillation taking vitamin K antagonists

G. Lip, V. Barrios, C. Escobar, 2017, International journal of clinical practice.

New blood pressure control goals, more rational but facilitating therapeutic inertia?

V. Barrios, C. Escobar, J. Llisterri, 2013, Journal of hypertension.

When kidney is the difference.

V. Barrios, C. Escobar, R. Echarri, 2011, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.

What is the place of percutaneous coronary intervention in the management of stable angina?

V. Barrios, C. Escobar, 2012, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.

Ischemic heart disease and women: more answers are needed.

V. Barrios, C. Escobar, 2012, Revista espanola de cardiologia.

Combined therapy in the treatment of hypertension: but which?

V. Barrios, C. Escobar, R. Echarri, 2009, Journal of hypertension.

Calcium channel blocker‐based combination therapy. The best approach in the treatment of high‐risk hypertension?

V. Barrios, C. Escobar, 2008, International journal of clinical practice.

Doxazosin and heart failure: to be or not to be.

V. Barrios, C. Escobar, A. Calderón, 2009, Journal of hypertension.

Telemedicine consultation for the clinical cardiologists in the era of COVID-19: present and future. Consensus document of the Spanish Society of Cardiology

V. Barrios, C. Escobar, Á. Cequier, 2020, Revista Española de Cardiología (English Edition).

Should angiotensin receptor blockers be the cornerstone of antihypertensive treatment in patients with obesity?

V. Barrios, C. Escobar, 2013, International journal of cardiology.

Which thiazide to choose as add-on therapy for hypertension?

V. Barrios, C. Escobar, 2014, Integrated blood pressure control.

Risk Factors Control in Diabetes

V. Barrios, C. Escobar, 2008, The Diabetes educator.

Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in daily clinical practice: the SARA study

V. Barrios, C. Escobar, A. Calderón, 2007, Journal of hypertension.

Diabetes and hypertension: which is the best approach?

V. Barrios, C. Escobar, 2009, Expert review of cardiovascular therapy.

Recommendations to improve lipid control in primary prevention patients. A consensus document of the Spanish Society of Cardiology

V. Barrios, C. Escobar, Á. Cequier, 2021, REC: CardioClinics.

[Effects of air pollution on mortality. Comments].

C. Escobar, J. Divisón, M. Seguí Díaz, 2015, Semergen.

A nutraceutical approach (Armolipid Plus) to reduce total and LDL cholesterol in individuals with mild to moderate dyslipidemia: Review of the clinical evidence.

P. Fasching, M. Banach, E. Bruckert, 2017, Atherosclerosis. Supplements.

[Lesions produced by radiofrequency ablation of the cavotricuspid isthmus in an experimental model].

C. Escobar, E. Bernal, A. Hernández Madrid, 2003, Revista espanola de cardiologia.

[Management of patients with dyslipidaemia in Spain. The Cardio Right Care Control of cardiovascular risk project].

V. Barrios, C. Escobar, V. Pallarés, 2020, Semergen.

Clinical Profile and Management of Patient Patients with Ischemic Heart Disease and/or Peripheral Artery Disease in Clinical Practice: The APALUSA Study

V. Barrios, C. Escobar, X. Garcia-Moll, 2022, Journal of clinical medicine.

Clinical Cardiology, Geriatric Cardiology, Heart Failure, and Transplantation 2015: A Selection of Topical Issues.

V. Barrios, C. Escobar, M. Martínez‐Sellés, 2016, Revista espanola de cardiologia.

Selección de temas de actualidad en cardiología clínica, cardiología geriátrica e insuficiencia cardiaca y trasplante 2015

V. Barrios, C. Escobar, A. Solé, 2016 .

Clinical characteristics, management, and one-year risk of complications among patients with heart failure with and without type 2 diabetes in Spain.

C. Escobar, A. Sicras-Mainar, M. Capel, 2021, Revista clinica espanola.

Baseline Characteristics and Clinical Management of Patients Attended in Primary Care Setting According to the Presence of Cardiovascular Disease

J. Badimón, C. Escobar, J. Llisterri, 2017 .

Antihypertensive drugs in daily clinical practice: are there differences between genders?

V. Barrios, C. Escobar, J. Jiménez-Nacher, 2009, European heart journal.

Not only after myocardial infarction

V. Barrios, C. Escobar, 2008, Heart.

Antihypertensive agents: are all of them equal?

V. Barrios, C. Escobar, 2008, Southern medical journal.

Heart failure and new drugs: should we be aware?

V. Barrios, C. Escobar, E. Melgarejo, 2009, International journal of clinical practice.

Angiotensin receptor blocker as adjunctive therapy for rhythm control in atrial fibrillation: results of the irbesartan-amiodarone trial.

C. Escobar, E. Bernal, Jian Peng, 2003, Cardiac electrophysiology review.

Blood pressure control in anticoagulated patients with hypertension and atrial fibrillation

V. Barrios, C. Escobar, J. Lobos, 2017, Blood pressure.

Have we attained the right control of hypertension? Consequences of the 2013 European Society of Hypertension/European Society of Cardiology and Eighth Joint National Committee recommendations.

V. Barrios, C. Escobar, F. J. Alonso-Moreno, 2014, Journal of hypertension.

Olmesartan medoxomil plus hydrochlorothiazide for treating hypertension

V. Barrios, C. Escobar, 2008, Expert opinion on pharmacotherapy.

Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with diabetes: data from the SARA study

V. Barrios, C. Escobar, A. Calderón, 2009, Journal of the renin-angiotensin-aldosterone system : JRAAS.

La consulta telemática para el cardiólogo clínico en tiempos de la COVID-19: presente y futuro. Documento de consenso de la Sociedad Española de Cardiología

V. Barrios, C. Escobar, Á. Cequier, 2020, Revista Española de Cardiología.

A new index to predict quality of anticoagulation control in patients on vitamin K antagonists: the DAFNE score.

V. Barrios, C. Escobar, J. Muñiz, 2020, Future cardiology.

Arrhythmogenic right ventricular dysplasia.

V. Barrios, C. Escobar, A. Calderón, 2009, Journal of the American College of Cardiology.

Mineralocorticoid receptor antagonists and acute heart failure

C. Escobar, L. Manzano, 2019, European journal of heart failure.

[Optimal duration of dual antiplatelet therapy].

C. Escobar, J. Divisón, 2015, Semergen.

Can dabigatran improve blood pressure control?

V. Barrios, C. Escobar, 2013, Future cardiology.

Effectiveness and safety of dabigatran compared to vitamin K antagonists in patients with atrial brillation: a systematic review and metanalysis

C. Escobar, 2021 .

Costs and healthcare utilisation of patients with heart failure in Spain

C. Escobar, M. Capel, N. Manito, 2020, BMC Health Services Research.

Individualizing the treatment of patients with heart failure with reduced ejection fraction: a journey from hospitalization to long-term outpatient care

C. Escobar, M. Crespo-Leiro, N. Farré, 2022, Expert opinion on pharmacotherapy.

Vaccination in Patients With Heart Failure: An Established Recommendation in Patients With Chronic Heart Disease.

V. Barrios, C. Escobar, 2019, JACC. Heart failure.

Gender and blood pressure control.

V. Barrios, C. Escobar, R. Echarri, 2008, Hypertension.

WHAT IS THE EVIDENCE ? Management of obesity in primary prevention of CKD Maintenance of a stable weight in the primary prevention of CKD

David W. Johnson, M. Vitolins, J. A. Divisón, 2013 .

Vaccination in Patients With Heart Disease. How Long Should We Wait?

V. Barrios, C. Escobar, 2019, Revista espanola de cardiologia.

[Is perioperative bridging anticoagulation necessary in patients with non-valvular atrial fibrillation?].

C. Escobar, J. Divisón, 2016, Semergen.

Patients' perceptions with dabigatran in patients with atrial fibrillation previously treated with vitamin K antagonists.

V. Barrios, C. Escobar, J. Gomez-Doblas, 2020, Journal of comparative effectiveness research.

Quality of life, adherence and satisfaction of patients with auricular fibrillation treated with dabigatran or vitamin K antagonists

V. Barrios, C. Escobar, G. Barón Esquivias, 2019, Revista Clínica Española (English Edition).

Red yeast rice for dyslipidaemias and cardiovascular risk reduction: A Position Paper of the International Lipid Expert Panel.

A. Sahebkar, M. Banach, G. Latkovskis, 2022, Pharmacological research.

Selection of the Best of 2017 in Clinical Cardiology. Continuum Healthcare Between Cardiology and Primary Care.

V. Barrios, C. Escobar, M. Ruiz-Ortíz, 2018, Revista espanola de cardiologia.

Should we make the risk stratification process more complex in patients with atrial fibrillation? Authors' reply.

A. Camm, C. Escobar, 2021, Europace.

Renal insufficiency should be included in stroke risk scores.

V. Barrios, C. Escobar, 2013, Kidney international.

Letter by Barrios et al regarding article, "Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women".

V. Barrios, C. Escobar, R. Echarri, 2010, Circulation.

SAMe-TT2R2 Score: Useful in All Patients With Nonvalvular Atrial Fibrillation?

V. Barrios, C. Escobar, J. Lobos, 2016, Revista espanola de cardiologia.

Rosuvastatin and cardiovascular continuum when time is important.

V. Barrios, C. Escobar, 2010, Journal of the American College of Cardiology.

Comments on the 2020 ESC/EACTS guidelines for the management of atrial fibrillation.

F. Atienza, H. Bueno, V. Barrios, 2021, Revista espanola de cardiologia.

Switching to sacubitril/valsartan or adding aldosterone antagonist: which first?

V. Barrios, C. Escobar, L. Manzano, 2019, ESC heart failure.

ACE Inhibitors and Angiotensin Receptor Blockers: a New Effective Non-Conventional Approach to Prevent Atrial Fibrillation

C. Escobar, E. Bernal, Jian Peng, 2004 .

Aliskiren: A Potential Antiarrhythmic Drug?

V. Barrios, C. Escobar, A. Calderón, 2012, Journal of clinical hypertension.

Resistant hypertension. What is the best approach?

V. Barrios, C. Escobar, 2009, Revista espanola de cardiologia.

Analysis of the prescription process of PCSK9 inhibitors in the cardiology departments of Spanish hospitals and optimization proposal. The IKIGAI study

V. Barrios, C. Escobar, Á. Cequier, 2021, Clínica e Investigación en Arteriosclerosis (English Edition).

N-acetylcysteine according to whether it is administered with ACE inhibitors or not.

V. Barrios, C. Escobar, R. Echarri, 2016 .

[Can the nephroprotective effect of N-acetylcysteine be optimized?].

V. Barrios, C. Escobar, R. Echarri, 2010, Revista espanola de cardiologia.

When the Clinical Trials Raise More Questions Than Answers: Blood Pressure Controversy Beyond the TRANSCEND Results

V. Barrios, C. Escobar, A. Calderón, 2009, Journal of clinical hypertension.

Control of Anticoagulation With Warfarin or Acenocoumarol in Spain. Do They Differ?

V. Barrios, C. Escobar, J. Lobos, 2015, Revista espanola de cardiologia.

Use of antithrombotic therapy according to CHA2DS2-VASc score in patients with atrial fibrillation in primary care.

V. Barrios, C. Escobar, A. Calderón, 2014, Revista espanola de cardiologia.

[Colchicine and pericarditis].

C. Escobar, J. Divisón, M. Seguí Díaz, 2015, Semergen.

Revisiting hypertension in rural areas. A new approach is required.

V. Barrios, C. Escobar, 2021, American journal of hypertension.

Gender Differences in the Management of Diabetic Patients with Hypertension and Chronic Ischemic Heart Disease

V. Barrios, C. Escobar, A. Calderón, 2009 .

Concomitance of cardiovascular comorbidities in the hypertensive population: not only in the United States.

V. Barrios, C. Escobar, R. Echarri, 2008, Archives of internal medicine.

Importance of electrocardiographic left ventricular hypertrophy in blood pressure control.

V. Barrios, C. Escobar, A. Calderón, 2011, Journal of hypertension.

Atrial fibrillation, an equivalent of cardiovascular disease risk.

V. Barrios, C. Escobar, 2020, European heart journal.

Degree of Anticoagulation Control in Patients With Atrial Fibrillation in Spain: Need to Minimize Biases and Contextualize Results. Response by Anguita Sánchez et al.

V. Barrios, C. Escobar, J. Lobos, 2016 .

Degree of Anticoagulation Control in Patients With Atrial Fibrillation in Spain: Need to Minimize Biases and Contextualize Results. Response Barrios et al.

V. Barrios, C. Escobar, J. Lobos, 2016, Revista espanola de cardiologia.

Use of healthcare resources and costs of acute cardioembolic stroke management in the Region of Madrid: The CODICE Study

C. Escobar, A. Gil-Núñez, F. Otero, 2015 .

Importance of medication adherence from the ONTARGET and TRANSCEND points of view

V. Barrios, C. Escobar, R. Echarri, 2009, Fundamental & clinical pharmacology.

Adverse events in clinical trials: is a new approach needed?

V. Barrios, C. Escobar, Luis Prieto, 2008, The Lancet.

Treatment of hypertriglyceridaemia with icosapent ethyl in patients with high/very high cardiovascular risk. Consensus document of the Sociedad Española de Cardiología [Spanish Society of Cardiology] and the Sociedad Española de Diabetes [Spanish Diabetes Society].

J. Tamargo, V. Sánchez-Margalet, V. Barrios, 2022, Endocrinologia, diabetes y nutricion.

Hypertension and children: should we be aware?

V. Barrios, C. Escobar, 2013, Hypertension.

First national registry of evolocumab in clinical practice in cardiology units in Spain. The RETOSS-CARDIO study.

V. Barrios, C. Escobar, V. Arrarte, 2020, Revista espanola de cardiologia.

Cost-effectiveness of Evolocumab.

V. Barrios, C. Escobar, 2018, Revista espanola de cardiologia.

Treating heart rate for the prevention of diabetes: the next step?

V. Barrios, C. Escobar, R. Echarri, 2009, American journal of hypertension.

Primary prevention. The cornerstone to reduce the burden of cardiovascular disease.

M. Banach, V. Barrios, C. Escobar, 2021, Revista espanola de cardiologia.

Antihypertensive effectiveness of lercanidipine administered using an electronic pillbox compared with usual care in a cohort of mild-to-moderately hypertensive patients: the ELECTRA study

L. Ruilope, V. Barrios, C. Escobar, 2007 .

Saline Irrigated Catheter Ablation for Pulmonary Vein Isolation in Pigs:

C. Escobar, E. Bernal, Jian Peng, 2004, Pacing and clinical electrophysiology : PACE.

Letter by Escobar et al Regarding Article, "On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF".

J. Górriz, V. Barrios, C. Escobar, 2016, Circulation.

Antihypertensive and organ-protective effects of benazepril

V. Barrios, C. Escobar, 2010, Expert review of cardiovascular therapy.

Variables associated with change in blood pressure control status after 1-year follow up in primary care: a retrospective analysis: the TAPAS study

C. Escobar, M. Leal, C. Suarez, 2014, European journal of preventive cardiology.

Risk Alteration for Atrial Fibrillation with DifferentAntihypertensive Drugs.

V. Barrios, C. Escobar, 2011, Journal of atrial fibrillation.

Efficacy and Safety of Single-Pill Amlodipine Besylate/Atorvastatin Calcium in the Management of Hypertension and Angina

V. Barrios, C. Escobar, 2011 .

Complementary mechanisms of action and rationale for the fixed combination of perindopril and indapamide in treating hypertension – update on clinical utility

V. Barrios, C. Escobar, 2010, Integrated blood pressure control.

Aliskiren in the Management of Hypertension

V. Barrios, C. Escobar, 2010, American journal of cardiovascular drugs : drugs, devices, and other interventions.

Clinical experience with a low-dose fixed combination of perindopril plus indapamide in a primary-care setting: the PRETEND study

V. Barrios, C. Escobar, J. Divisón, 2007 .

Comments on the 2018 ESC/ESH Guidelines for the Management of Arterial Hypertension.

A. Evangelista, H. Bueno, B. Ibáñez, 2019, Revista espanola de cardiologia.

Comments on the 2011 ESC/EAS guidelines for the management of dyslipidemias. A report of the Task Force of the Clinical Practice Guidelines Committee of the Spanish Society of Cardiology

E. Guallar, B. Ibáñez, G. Sanz, 2011 .

Electrocardiographic Left Ventricular Hypertrophy Regression Induced by an Angiotensin Receptor Blocker‐Based Regimen in Hypertensive Patients With the Metabolic Syndrome: Data From the SARA Study

V. Barrios, C. Escobar, A. Calderón, 2008, Journal of clinical hypertension.

Prevalence of the metabolic syndrome in patients with hypertension treated in general practice in Spain: an assessment of blood pressure and low-density lipoprotein cholesterol control and accuracy of diagnosis.

V. Barrios, C. Escobar, E. Alegrı́a, 2007, Journal of the cardiometabolic syndrome.

Changing paradigms: from prevention of thromboembolic events to improved survival in patients with atrial fibrillation.

A. Camm, C. Escobar, A. Camm, 2020, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

A Delphi consensus on the management of oral anticoagulation in patients with non-valvular atrial fibrillation in Spain: ACOPREFERENCE study

C. Escobar, X. Borrás, C. González-Juanatey, 2020, PloS one.

New evidences for old concerns with oral anticoagulation in atrial fibrillation: focus on dabigatran

V. Barrios, C. Escobar, 2012, Expert opinion on pharmacotherapy.

Feasibility and safety of pulmonary vein isolation by high-power short-duration radiofrequency application: short-term results of the POWER-FAST PILOT study

J. Merino, C. Escobar, J. L. López Sendón, 2019, Journal of Interventional Cardiac Electrophysiology.

New evidence, new controversies: a critical review of the European Society of Cardiology 2010 clinical practice guidelines on atrial fibrillation.

J. Merino, A. Pedrote, A. Fernández-Ortiz, 2012, Revista espanola de cardiologia.

Evaluation of SAMe-TT2R2 score and other clinical factors influencing the quality of anticoagulation therapy in non-valvular atrial fibrillation: a nationwide study in Spain

V. Barrios, C. Escobar, S. Fuentes, 2016, Current medical research and opinion.

Edoxaban in the prevention and treatment of thromboembolic complications from a clinical point of view

V. Barrios, C. Escobar, 2015, Expert review of cardiovascular therapy.

Rivaroxaban: a once-daily anticoagulant for the prevention of thromboembolic complications

V. Barrios, C. Escobar, 2013, Expert review of cardiovascular therapy.

Rate-Control vs Rhythm-Control for Atrial Fibrillation: A Controversy Reluctant to Die in the Era of Dronedarone?

J. Merino, V. Barrios, C. Escobar, 2013 .

The Role of Angiotensin Receptor Blockers and/or Angiotensin Converting Enzyme Inhibitors in the Prevention of Atrial Fibrillation in Patients with Cardiovascular Diseases:

C. Escobar, J. Zamora, E. Bernal, 2004, Pacing and clinical electrophysiology : PACE.

N-acetylcysteine for the prevention of atrial fibrillation: beyond its antioxidant effect.

V. Barrios, C. Escobar, V. Lahera, 2008, European heart journal.

Diagnosis of elderly patients with heart failure

J. Cleland, M. Flather, C. Escobar, 2012, European journal of heart failure.

Clinical applicability of B-type natriuretic peptide in patients with suspected heart failure in primary care in Spain: the PANAMA study

V. Barrios, C. Escobar, F. Ridocci, 2011, Expert review of cardiovascular therapy.

Detection of unrecognized clinical heart failure in elderly hypertensive women attended in primary care setting

V. Barrios, C. Escobar, J. Llisterri, 2010, Blood pressure.

Clinical profile and management of patients with chronic ischemic heart disease according to age in the population daily attended by cardiologists in Spain The ELDERCIC study.

V. Barrios, C. Escobar, N. Murga, 2010, European journal of internal medicine.

Atrial fibrillation and dabigatran: has the time come to use new anticoagulants?

V. Barrios, C. Escobar, D. Jiménez, 2010, Cardiovascular therapeutics.

Implications of edoxaban in the prevention and treatment of thromboembolic complications in clinical practice.

V. Barrios, C. Escobar, 2016, Future cardiology.

Candesartan: from left ventricular hypertrophy to heart failure, a global approach

V. Barrios, C. Escobar, A. Calderón, 2007, Expert review of cardiovascular therapy.

Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in clinical practice

V. Barrios, C. Escobar, A. Coca, 2012, Expert review of cardiovascular therapy.

Valsartan–amlodipine–hydrochlorothiazide: the definitive fixed combination?

V. Barrios, C. Escobar, 2010, Expert review of cardiovascular therapy.

Rosuvastatin along the cardiovascular continuum: from JUPITER to AURORA

V. Barrios, C. Escobar, 2009, Expert review of cardiovascular therapy.

An evaluation of the latest evidence relating to renin–angiotensin system inhibitors

V. Barrios, C. Escobar, 2013, Expert opinion on drug metabolism & toxicology.

Atrial Fibrillation And Coronary Heart Disease:Fatal Attraction.

V. Barrios, C. Escobar, R. Echarri, 2009, Journal of atrial fibrillation.

Comparison of the effects of doxazosin and atenolol on target organ damage in adults with type 2 diabetes mellitus and hypertension in the CARDHIAC study: a 9-month, prospective, randomized, open-label, blinded-evaluation trial.

V. Barrios, C. Escobar, A. Calderón, 2008, Clinical therapeutics.

Prevalence and clinical profile and management of peripheral arterial disease in elderly patients with diabetes.

C. Escobar, L. Manzano, D. Vinuesa, 2011, European journal of internal medicine.

Clinical implications of different biomarkers in elderly patients with heart failure.

C. Escobar, L. Manzano, N. Ribas, 2014, Biomarkers in medicine.

Tolerability of high doses of lercanidipine versus high doses of other dihydropyridines in daily clinical practice: the TOLERANCE Study.

J. Segura, V. Barrios, C. Escobar, 2008, Cardiovascular therapeutics.

Patients with atrial fibrillation in a primary care setting: Val-FAAP study.

V. Barrios, C. Escobar, A. Calderón, 2012 .

Improving cardiovascular protection: focus on a cardiovascular polypill.

V. Barrios, C. Escobar, 2016, Future cardiology.

Treatment and blood pressure control in Spain during 2002–2010

V. Barrios, C. Escobar, J. Llisterri, 2012, Journal of hypertension.

Blood Pressure and Lipid Goal Attainment in the Hypertensive Population in the Primary Care Setting in Spain

V. Barrios, C. Escobar, E. Alegrı́a, 2007, Journal of clinical hypertension.

Cardiovascular risk profile and risk stratification of the hypertensive population attended by general practitioners and specialists in Spain. The CONTROLRISK study

L. Ruilope, V. Barrios, C. Escobar, 2007, Journal of Human Hypertension.

Clinical Profile and Management of Patients With Hypertension and Chronic Ischemic Heart Disease According to BMI

V. Barrios, C. Escobar, A. Calderón, 2010, Obesity.

Is a New Crash Coming

Carlos Escobar, Vivencio Barrios, V. Barrios, 2012 .

SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other glucose‐lowering drugs in patients with type 2 diabetes mellitus to prevent cardiovascular events: A systematic review

V. Barrios, C. Escobar, I. Solá, 2020, Diabetic medicine : a journal of the British Diabetic Association.

Impact of different models of improvement of continuity of care on lipid control and the delay of visits to cardiology.

C. Escobar, F. Calvo Iglesias, J. Cosín-Sales, 2019, Future cardiology.

Canagliflozin: metabolic, cardiovascular and renal protection.

V. Barrios, C. Escobar, 2021, Future cardiology.

Regression of left ventricular hypertrophy by a candesartan-based regimen in clinical practice The VIPE study

V. Barrios, C. Escobar, J. Moya, 2006, Journal of the renin-angiotensin-aldosterone system : JRAAS.

Concomitant Rivaroxaban and Dronedarone Administration in Patients With Nonvalvular Atrial Fibrillation.

J. López-Sendón, J. Merino, C. Escobar, 2017, Revista espanola de cardiologia.

Selection of the Best of 2016 in Clinical Cardiology: Continuum of Care; Relationship Between Cardiology and Primary Care.

V. Barrios, C. Escobar, A. Calderón, 2017, Revista espanola de cardiologia.

Reply to f. Catalá-López et al.

V. Barrios, C. Escobar, J. Llisterri, 2013, Journal of hypertension.

Importance of Bnp changes during the follow-up in elderly outpatients with heart failure.

C. Escobar, J. D. del Rey, L. Manzano, 2014, Clinical biochemistry.

Evolution of clinical profile, treatment and blood pressure control in treated hypertensive patients according to the sex from 2002 to 2010 in Spain

V. Barrios, C. Escobar, J. Llisterri, 2015, Journal of hypertension.

Evolution of therapy inertia in primary care setting in Spain during 2002–2010

V. Barrios, C. Escobar, A. Calderón, 2014, Journal of hypertension.

[Utility of aspirin in patients undergoing noncardiac surgery. Commentary].

C. Escobar, J. Divisón, M. Seguí Díaz, 2014, Semergen.

Searching the place of pitavastatin in the current treatment of patients with dyslipidemia

J. Zamorano, V. Barrios, C. Escobar, 2013, Expert review of cardiovascular therapy.

New therapeutic progress in cardiorenal protection of the hypertensive patient with a focus on olmesartan

F. Álvaro, V. Barrios, C. Escobar, 2009 .

Sex Differences in the Hypertensive Population With Chronic Ischemic Heart Disease

V. Barrios, C. Escobar, C. de Pablo, 2008, Journal of clinical hypertension.

Direct Oral Anticoagulants Versus Vitamin K Antagonists in Real-life Patients With Atrial Fibrillation. A Systematic Review and Meta-analysis.

C. Escobar, M. Martínez-Zapata, J. Martí-Almor, 2019, Revista espanola de cardiologia.

Recommendations to improve lipid control. Consensus document of the Spanish Society of Cardiology.

L. Pérez de Isla, V. Barrios, C. Escobar, 2019, Revista espanola de cardiologia.

Clinical profile and management of hypertensive patients with chronic ischemic heart disease and renal dysfunction attended by cardiologists in daily clinical practice

V. Barrios, C. Escobar, C. de Pablo, 2008, Journal of hypertension.

Which patients could benefit from the use of bempedoic acid in clinical practice?

V. Barrios, C. Escobar, 2022, Revista espanola de cardiologia.

Low-dose fixed combination of perindopril plus indapamide in the diabetic hypertensive population

V. Barrios, C. Escobar, J. Divisón, 2008, Expert review of cardiovascular therapy.

COVID-19 and QT interval prolongation: more than just drug toxicity?

J. Merino, C. Escobar, A. Iniesta, 2020, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

Comments on the 2019 ESC guidelines on supraventricular tachycardia.

J. Brugada, A. Evangelista, J. Merino, 2020, Revista Española de Cardiología.

Clinical profile and blood pressure control in patients managed in primary care in Spain: are there any differences between the young and the old?

V. Barrios, C. Escobar, A. Calderón, 2013, Revista espanola de cardiologia.

Importance of perception for blood pressure control.

V. Barrios, C. Escobar, C. de Pablo, 2008, Archives of internal medicine.

[Blood pressure and lipid control and coronary risk in the hypertensive population attended in Primary Care setting in Spain. The PRESCOT study].

V. Barrios, C. Escobar, E. Alegrı́a, 2007, Revista clinica espanola.

Pulse pressure and the metabolic syndrome in patients with hypertension.

V. Barrios, C. Escobar, R. Echarri, 2009, Journal of the cardiometabolic syndrome.

Letter by Barrios et al regarding article, "Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study".

V. Barrios, C. Escobar, R. Echarri, 2009, Circulation.

Glycemic Control Using Individualized Targets Among Diabetic Patients in Spain: A Population-Based Study

V. Barrios, C. Escobar, 2016 .

First national registry on the effectiveness and safety of evolocumab in clinical practice in patients attended in cardiology in Spain. The RETOSS-CARDIO study

V. Barrios, C. Escobar, V. Arrarte, 2020 .

First national registry on the effectiveness and safety of evolocumab in clinical practice in patients attended in cardiology in Spain. The RETOSS-CARDIO study.

V. Barrios, C. Escobar, V. Arrarte, 2020, Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.

[Cardiotoxicity. A reality that the primary care physician should be aware].

C. Escobar, J. Divisón, 2017, Semergen.

[Adequacy of the treatment of hypertensive patients with metabolic syndrome].

V. Barrios, C. Escobar, E. Alegrı́a, 2007, Medicina clinica.

[From clinical trials to clinical practice. Experience with rivaroxaban in the anticoagulant treatment of patients with non-valvular atrial fibrillation].

V. Barrios, C. Escobar, 2017, Semergen.

Prevalence of renal dysfunction according to the type of atrial fibrillation and anticoagulation treatment in patients who attended primary care in Spain.

J. Zamorano, V. Barrios, C. Escobar, 2014, Future cardiology.

[Baseline clinical characteristics and management of patients included in IBERICAN study].

J. Badimón, V. Barrios, C. Escobar, 2015, Semergen.

Real-World Attainment of Low-Density Lipoprotein Cholesterol Goals in Patients at High Risk of Cardiovascular Disease Treated with High-Intensity Statins: The TERESA Study

V. Barrios, C. Escobar, X. Pintó, 2023, Journal of Clinical Medicine.